ReviewFrontiers in immunology2021
Differentiation and Regulation of T
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 202 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
202 citing papers in PubMed, 2 syntheses or guidelines pooled it, 319 citations in OpenAlex.
- Combined immunotherapy with dendritic cells and cytokine-induced killer cells for solid tumors: a systematic review and meta-analysis of randomized controlled trials.Journal of translational medicine · 2024Pooled it
- Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination.Frontiers in immunology · 2021Pooled it
- Phase II Trial of Nivolumab in Metastatic Rare Cancer with dMMR or MSI-H and Relation with Immune Phenotypic Analysis (the ROCK Trial).Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Trial
- Why CD4+ T cells matter in adoptive cell therapy for solid cancers.Immuno-oncology technology · 2026Review
- Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency.Biomaterials · 2026Article
- Cervical Cytokine Profile in High-Grade Squamous Intraepithelial Lesions.Cytopathology : official journal of the British Society for Clinical Cytology · 2026Article
- Natural-Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti-Tumor Immunity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Dendritic cell vaccines: Current research progress, challenges, and opportunities.Genes & diseases · 2026Review
- Review
- Chorus line in oral squamous cell carcinoma: How stromal and immune players orchestrate tumor progression (Review).International journal of molecular medicine · 2026Review
- MAP3K1: A Multifunctional Kinase at the Crossroads of Cancer Progression and Tumor Suppression.Cells · 2026Review
- Recombinant CALR polarizes and activates macrophages in tumors.Molecular therapy. Oncology · 2026Article
- Antigen Specificity and Cell Engineering Determine CAR T Cell Efficacy in Group 3 Medulloblastoma.Research square · 2026Article
- Overexpression, clinical significance and potential mechanisms of protein kinase D1 in hepatocellular carcinoma: multi-omic analyses and pharmacological insights.Functional & integrative genomics · 2026Article
- DNA methylation-mediated silencing of MEOX1 promotes glycolysis and immune evasion in colorectal cancer cells through inhibition of GLP2R transcription.Cell & bioscience · 2026Article
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- DIAPH3 is a multifaceted prognostic biomarker that links immunotherapy response to tumor microenvironment in prostate cancer.Discover oncology · 2026Article
- When genetics meets immunology: the assessment of genetic and immunological backgrounds in advanced NSCLC patients treated with immunotherapy - preliminary study.Journal of applied genetics · 2026Article
- 3M-052 combined inhibitory anti-TNFR2 synergistically suppresses colon cancer progression.Frontiers in immunology · 2026Article
- Nanoparticles that modulate immune cells - an important strategy for the future treatment of tumors.Frontiers in immunology · 2026Review
142 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current success of immunotherapy in cancer has drawn attention to the subsets of T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.